ArticleTargeted oncology2021

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Jean-Pierre Delord et al.PubMed ↗Publisher ↗

No numbers read from the abstract.